Kraj: Kanada
Język: angielski
Źródło: Health Canada
IRBESARTAN
PHARMASCIENCE INC
C09CA04
IRBESARTAN
75MG
TABLET
IRBESARTAN 75MG
ORAL
100/500
Prescription
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0131700001; AHFS:
APPROVED
2011-03-21
_pms-IRBESARTAN (irbesartan) _ _Page 1 of 35_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR PMS-IRBESARTAN Irbesartan Tablets Tablets, 75 mg, 150 mg and 300 mg, Oral USP Angiotensin II AT 1 Receptor Blocker PHARMASCIENCE INC. 6111 Royalmount Avenue, Suite # 100 Montréal, Québec H4P 2T4 www.pharmascience.com Submission Control Number: 271234 Date of Initial Authorization: March 21, 2011 Date of Revision: March 2, 2023 _pms-IRBESARTAN (irbesartan) _ _Page 2 of 35_ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS 06/2021 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ....................................................................................... 2 TABLE OF CONTENTS ............................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................................ 4 1 INDICATIONS ...................................................................................................................... 4 1.1 Pediatrics .................................................................................................................... 4 1.2 Geriatrics ..................................................................................................................... 4 2 CONTRAINDICATIONS ....................................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 5 4 DOSAGE AND ADMINISTRATION ..................................................................................... 5 4.1 Dosing Considerations ................................................................................................ 5 4.2 Recommended Dose and Dosage Adjustment ............................................................ 5 4.4 Administration ....................................... Przeczytaj cały dokument